Catalog No.S3024

Lamotrigine is a novel anticonvulsant drug for inhibition of 5-HT with IC50 of 240 μM and 474 μM in human platelets and rat brain synaptosomes, and also is a sodium channel blocker.

Price Stock Quantity  
USD 120 In stock
USD 90 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Lamotrigine Chemical Structure

Lamotrigine Chemical Structure
Molecular Weight: 256.09

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Lamotrigine is available in the following compound libraries:

Product Information

  • Compare Sodium Channel Chemicals
    Compare Sodium Channel Products
  • Research Area

Product Description

Biological Activity

Description Lamotrigine is a novel anticonvulsant drug for inhibition of 5-HT with IC50 of 240 μM and 474 μM in human platelets and rat brain synaptosomes, and also is a sodium channel blocker.
Targets Sodium channel [1] 5-HT (human platelets) [1] 5-HT (rat brain synaptosomes) [1]
IC50 240 μM 474 μM
In vitro Lamotrigine stabilises presynaptic neuronal membranes by blockade of voltage-dependent sodium channels, thus preventing the release of excitatory neurotransmitters, particularly glutamate and aspartate. [1] In rat cerebral cortex tissue incubated with veratrine 10 mg/L, lamotrigine is twice as potent in inhibiting the release of glutamate and aspartate (ED 50 = 5.38 mg/L for each) than the release of GABA (ED50 = 11.2 mg/L), and is much less potent in inhibiting acetylcholine release (ED50 = 25.6 mg/L) when cortical slices is exposed to veratrine 75 mg/L. Basal glutamate release is unaffected . [2]Lamotrigine inhibits high-frequency sustained repetitive firing of sodium-dependent action potentials, indicating a direct effect on voltage-activated sodium channels. [3] Lamotrigine does not induce PCP-like central nervous system (CNS) effects, does not act by direct inhibition at the NMDA receptor, and would be expected to be devoid of the undesirable effects associated with NMDA blockade. [4]
In vivo In mice and rats, lamotrigine prevents MES- and pentetrazol-induced hindlimb extension, suggesting an antiepileptic profile in animals. These effects peak 1 hour after lamotrigine administration and persist for more than 24 hours. [4] Lamotrigine is active in the electrically evoked EEG after-discharge test, which is thought to indicate activity against both simple and complex partial seizures. After-discharge duration is reduced dose-dependently by lamotrigine in rats at intravenous doses >5 mg/kg. [5]

Protocol(Only for Reference)

Kinase Assay: [3]

Electrophysiology In electrophysiological experiments, neurons bathed in control medium responds to 500-ms depolarizing pulses with trains of action potentials termed sustained repetitive firing (SRF). Increasing the magnitude of depolarization results in an increased number and frequency of action potentials. Typically a depolarizing current step of l-l.5 nA is sufficient to evoke SRF. To test the anticonvulsant effect, the blocking of SRF throughout the depolarizing current pulse is analyzed.

Animal Study: [3]

Animal Models Dog/Rat
Formulation suspended in 0.25% methylcellulose solution
Dosages 4.5 and 11.7 mg /kg in dogs and rats, respectively
Administration i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Goa KL, et al. Drugs, 1993, 46(1), 152-176.

[2] Leach MJ, et al. Epilepsia, 1986, 27(5), 490-497.

view more

Clinical Trial Information( data from, updated on 2015-11-14)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02513654 Active, not recruiting Bipolar Disorder GlaxoSmithKline September 2015 Phase 1
NCT02556060 Active, not recruiting Addiction Taipei City Hospital|Chang Gung Memorial Hospital September 2015 Phase 2|Phase 3
NCT02404168 Not yet recruiting Epilepsy University of Maryland April 2015 Phase 4
NCT02389712 Recruiting Bipolar Disorder Mayo Clinic March 2015 Phase 4
NCT02374567 Recruiting Dementia|Depression|Schizophrenia|Psychosomatic Disorders|Anxiety Disorders Hannover Medical School January 2015 Phase 3

view more

Chemical Information

Download Lamotrigine SDF
Molecular Weight (MW) 256.09


CAS No. 84057-84-1
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms BW-430C
Solubility (25°C) * In vitro DMSO 10 mg/mL (39.04 mM)
Ethanol 3 mg/mL (11.71 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Sodium Channel Products

  • Elacridar (GF120918)

    Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor.

  • Verdinexor (KPT-335)

    Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

  • Ouabain

    Ouabain is a selective Na+/K+, -ATPase inhibitor, binds to α2 /α3 subunit with Ki of 41 nM/15 nM.

    Features:A glycoside poison that binds to and inhibits the action of the Na+/K+ pump in the cell membrane.

  • Amiloride HCl

    Amiloride HCl is a relatively selective inhibitor of the epithelial sodium channel (ENaC), used in the management of hypertension and congestive heart failure.

  • Digoxin

    Digoxin is a sodium-potassium pump inhibitor, used in the treatment of atrial fibrillation and heart failure.

  • Rufinamide

    Rufinamide is a voltage-gated sodium channel blocker, used an anticonvulsant medication.

  • Zonisamide

    Zonisamide is a voltage-dependent sodium channel and T-type calcium channel blocker, used as an antiepileptic drug.

  • Bupivacaine HCl

    Bupivacaine HCl binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, used for treating cardiac arrhythmias.

  • Riluzole

    Riluzole is a drug used to treat amyotrophic lateral sclerosis.

Recently Viewed Items

Tags: buy Lamotrigine | Lamotrigine ic50 | Lamotrigine price | Lamotrigine cost | Lamotrigine solubility dmso | Lamotrigine purchase | Lamotrigine manufacturer | Lamotrigine research buy | Lamotrigine order | Lamotrigine mouse | Lamotrigine chemical structure | Lamotrigine mw | Lamotrigine molecular weight | Lamotrigine datasheet | Lamotrigine supplier | Lamotrigine in vitro | Lamotrigine cell line | Lamotrigine concentration | Lamotrigine nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us